A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

DxVx, Won the Governmental Project to Develop Diagnostic Sensor Kit for Adult Diseases

DxVx announced today that it won the national project, ‘Korea-led K-Sensor Technology Development for Market Leadership’ supported by the Ministry of Trade, Industry and Energy and managed by the Korea Evaluation Institute of Industrial Technology.

The main task is ‘Development of optical sensor system for early diagnosis of adult diseases based on biomarkers in urine’, which is to discover biomarkers (biochemical substances such as volatile organic compounds and glucose) in urine for full-time monitoring and early diagnosis of various adult diseases such as diabetes and prostate cancer. It also aims to develop an in vitro POCT (point-of-care device) capable of measuring various biomarkers by applying MEMS (microelectromechanical system) technology, optical technology, semiconductor technology for signal processing, and artificial intelligence analysis technology.

In this project, which will be carried out over three years with a total budget of about $3.6 million($2.8 million in government support), Dx&Vx will lead the development as a lead company. It will be developed in collaboration with the Korea Electronics Technology Institute (KETI), the Department of Urology at Hanyang University College of Medicine, and the Department of Electrical and Electronics Engineering at Korea University. COREE Group will be responsible for final commercializing.

With winning of this project, Dx&Vx expects to further accelerate its total biohealthcare solution business. In particular, after product development, Dx&Vx plans to launch the product in China through its Chinese subsidiary company and global sales through COREE Group’s overseas network, which is expected to increase its sales and grow the in vitro diagnostic business.

“Starting with the diagnostic development business that combines biotechnology and semiconductors, we will expand the development of additional modules using AI and IoT technologies, data analysis algorithms, and technologies for early diagnosis,” said an official from Dx&Vx. “We will solve the unmet need for early diagnosis of various adult diseases and bio healthcare problems due to the global aging trend, and provide total healthcare solutions using micro-system semiconductors for diagnosis and therapeutic management.”

The products to be developed in the future are expected to be utilized for various adult diseases such as diabetes, hypertension, prostate cancer, and bladder cancer, and will be presented in the form of a non-invasive ‘POCT equipment and cartridges, a sensor system for early diagnosis of adult diseases’.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy